Business & Economy
Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s
Source: Business News · Published
Eli Lilly and Novo are developing new amylin drugs that serve as another biological lever to pull in treating obesity and diabetes.
Eli Lilly and Novo are developing new amylin drugs that serve as another biological lever to pull in treating obesity and diabetes.
Related stories
Eli Lilly says closely watched combo obesity regimen boosts weight loss in mid-stage trial
Lilly said it plans to start Phase 3 trials on the combo regimen adding its amylin drug eloralintide to tirzepatide at the end of the year.
Business News ·
People switching to Novo's Wegovy pill from obesity injections kept losing weight in real-world study
The data on Novo's Wegovy pill suggests that patients may not need to take weekly injections forever, but can instead opt for more convenient treatments.
Business News ·
We're saving £100 a month into pensions for our toddler and baby - here's why
A growing number of parents are opening retirement funds for their children.
feeds.bbci.co.uk ·
Lucid's Q3 deliveries fall 6.7% as EV maker cuts production to align with demand
Lucid delivered 3,806 EVs and produced 2,954 vehicles during the third quarter. That compared with 4,078 deliveries on production of 3,891 vehicles a year earlier.
Business News ·
US supreme court hears big oil’s bid to block climate damage lawsuits
How court will lean is unclear amid Suncor Energy and ExxonMobil’s attempt to stop lawsuits at state level The US supreme court began its new nine-month term hearing arguments on Monday in a major case in which big oil companies attempted to strike a fatal blow against lawsuits t
Business | The Guardian ·